Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2020Yazar
Peled, NirGillis, Roni
Kılıçkap, Saadettin
Froesch, Patrizia
Orlov, Sergei
Filippova, Elena
Demirci, Umut
Christopoulos, Petros
Çiçin, İrfan
Buğdaycı Basal, Fatma
Yılmaz, Cengiz
Fedor, Moiseenko
Korkmaz, Taner
Paydaş, Semra
Gautschi, Oliver
Zırtıloğlu, Alişan
Eralp, Yeşim
Yeşil Çınkır, Havva
Sezer, Ahmet
Erman, Mustafa
Tural, Deniz
Turna, Hande
Mazieres, Julien
Dudnik, Elizabeth
Reguart, Noemi
Camidge, David Ross
Ng, Terry L.
Çay Şenler, Filiz
Beypınar, İsmail
Yazılıtaş, Doğan
Demirkazık, Ahmet
Karaoğlu, Aziz
Okutur, Kerem
Coşkun, Hasan Şenol
Şendur, Mehmet Ali Nahit
Işıkdoğan, Abdurrahman
Çabuk, Devrim
Yumuk, Perran Fulden
Yıldız, İbrahim
Kaplan, Mehmet Ali
Özyılkan, Özgür
Öztop, İlhan
Ölmez, Ömer Fatih
Aydın, Kübra
Aydıner, Adnan
Meydan, Nezih
Grinberg, Roxana Denisa
Roisman, Laila C.
Üst veri
Tüm öğe kaydını gösterKünye
Peled, N., Gillis, R., Kılıçkap, S., Froesch, P., Orlov, S., Filippova, E. ... Roisman, L. C. (2020). Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients. Lung cancer, 148, 48-54. https://dx.doi.org/10.1016/j.lungcan.2020.07.022Özet
Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.Methods: 123 patients were enrolled retrospectively (data cut-off 1/1/2019). Lorlatinib was administered through an early access program for patients with no other available therapy. Outcome and response were defined by each investigator upon RECIST 1.1 criteria.Results: 106 ALK(+) and 17 ROS1(+) patients recruited from 8 different countries. The ALK( + ) cohort included 50 % males, 73 % never-smokers and 68 % with brain metastases. Extracranial (EC) and intracranial (IC) response rates (RR) were 60 % and 62 %, with disease control rates (DCR) of 91 % and 88 % respectively. Mean duration of therapy (DoT) was 23.9 +/- 1.6 months and median overall survival (mOS) was 89.1 +/- 19.6 months. ROS1 cohort enrolled 53 % males, 65 % never-smokers and 65 % had brain metastases. EC and IC RR were 62 % and 67 % with DCR of 92 % and 78 % respectively. Median DoT was 18.1 +/- 2.5 months and mOS of 90.3 +/- 24.4 months. OS and DoT in both cohorts were not significantly correlated with line of therapy nor other parameters.The most common adverse events of any grade were peripheral edema (48 %), hyperlipidemia (47 %), weight gain (25 %) and fatigue (30 %). CNS adverse events such as cognitive effect of grade 1-2 were reported in 18 % of patients.Conclusion: Lorlatinib shows outstanding EC/IC efficacy in ALK/ROS1(+) NSCLC. The observed mOS of 89 +/- 19 months in ALK(+) NSCLC supports previous reports, while mOS from of 90 +/- 24 months is unprecedented for ROS1( + ) NSCLC.
WoS Q Kategorisi
Q1Scopus Q Kategorisi
Q1Kaynak
Lung cancerCilt
148Koleksiyonlar
- Makale Koleksiyonu [3642]
- PubMed İndeksli Yayınlar Koleksiyonu [4039]
- Scopus İndeksli Yayınlar Koleksiyonu [6271]
- WoS İndeksli Yayınlar Koleksiyonu [6416]